Catalogue

Source
A chicken was immunized with a peptide representing the splice junction of osteopontin-c (Ac-SEEKQNAVSC-COOH). After multiple immunizations, eggs were collected and IgY was purified from the egg yolk. The antibody was affinity purified on an osteopontin-c peptide column and conjugated to fluorescein isothiocyanate.

Product

Product Form: Fluorescein conjugated

Formulation: Phosphate buffered saline‚ pH 7.2‚ 50% glycerol with 0.075% sodium azide

Purification Method: Egg-yolk derived IgY Affinity Purified

Concentration: See vial for concentration.

Applications
This antibody is suitable for immunohistochemical applications. Optimal working dilutions should be determined for your particular assay conditions.

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles.

Shipping Conditions: Ship at ambient temperature

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. He B, Mirza M, Weber GF., 2006. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192–2202. 2. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF., 2008. Osteopontin-c is a selective marker of breast cancer. Int J Cancer: 122:2646. 3. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA., 2009. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146:232-40. 4. Tilli, TM, Thuler LC, Matos, AR, Coutinho-Camillo, CM, Soares, FA, da Silva, EA, Neves, AF, Goulart, LR and ER Gimba. 2011.Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92:13-19. 5. Tilli, TM, Mello, KD, Ferreira, LB, Matos, AR, Accioly, MTS, Faria, PAS., Bellahcène, A, Castronovo, V and ER Gimba. 2012. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72:1688-1699. 6. Zhang, MX, Xu YJ, Zhu MC and F. Yan. 2013. Overexpressed Osteopontin-c as a Potential Biomarker for Esophageal Squamous Cell Carcinoma. Asian Pac J Cancer Prev 14: 7315-9 7. T. Martins Tilli, L. Bueon Ferreira and E.R. Pereira Gimba. 2015. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through P13K/Akt and androgen receptor signaling. Oncol. Lett. 9: 1845-50. 8. Zduniak K., Ziolkowski, P. Ahlin C., Agrawal, A., Blomqvist, C., Fjallskog, M.L., and G.F. Weber. 2015. Nuclear Osteopontin-c is a prognostic breast cancer marker. Br. J. Cancer 112:729-38. 9. Zduniak, K, Agrawal, A, Agriwal, S, Hossain, MM, Ziolkowski, P and GF Weber, 2016. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer 16:441.

Safety Datasheet(s) for this product: